Navigation Links
Neogen Acquires International Diagnostic Systems
Date:5/4/2009

LANSING, Mich., May 4 /PRNewswire-FirstCall/ -- Neogen Corporation (Nasdaq: NEOG) has acquired International Diagnostic Systems Corp (IDS), a leading developer, manufacturer and marketer of test kits to detect drug residues in food and animal feed, and drugs in forensic and animal samples.

Based in St. Joseph, Mich., IDS has been in business for more than 20 years, and offers approximately 40 products. In addition to significant sales in the United States, IDS has distribution in France, Italy, Spain, Germany, and China. A key recent focus of the company has been the food safety market for testing animal feed, meat products, and seafood. IDS recorded revenues of approximately $2 million in its most recently completed fiscal year. Terms of the acquisition were not disclosed.

A part of IDS's operations will be relocated to and integrated with Neogen's Lexington, Ky., facilities. The company's research and development operations, and key IDS employees, will remain in IDS's Michigan facilities.

"We are pleased to have several valuable employees, with many years of experience at IDS, join Neogen," said Lon Bohannon, Neogen's president. "International Diagnostic's products are complementary and a nice fit with our existing forensic and drug detection product lines. The IDS purchase also provides Neogen with key collaborative relationships with influential industry partners, and increased access to important international markets, including China."

"We've had a long-standing respect for Neogen as both a competitor and a leader in supplying solutions for food and animal safety," said Deborah Morris, IDS's president. "We are pleased to be joining Neogen and helping to expand its markets."

IDS has been providing rapid immunoassay products for use in agriculture and veterinary markets since 1986. In the late 1980s, IDS began selling drug monitoring products to the horse and dog racing industry. In recent years, IDS expanded into the human forensics drug testing market.

Neogen Corporation develops and markets products dedicated to food and animal safety. The company's Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. Neogen's Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides.

Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's most recently filed Form 10-K.


'/>"/>
SOURCE Neogen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NeoGenomics, Inc. Reports First Quarter 2009 Financial Results
2. NeoGenomics Schedules its Q1 2009 Earnings Release for April 23, 2009
3. NeoGenomics Appoints Douglas M. VanOort as Executive Chairman and Interim Chief Executive Officer
4. Neogen Reactivates Share Repurchase Program
5. NeoGenomics to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
6. Webcast Alert: Neogen Corporation To Announce 2nd Quarter Results
7. NeoGenomics Schedules Its Q3 2008 Earnings Release for November 6, 2008
8. NeoGenomics to Present at the Noble Financial Equity Conference
9. NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008
10. NeoGenomics Announces Results for the 3rd Quarter 2007
11. NeoGenomics, Inc. Schedules its Q3 07 Earnings Conference Call For Wednesday, November 14, 2007 at 11:00 AM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... ... Cellairis is a worldwide mobile device and computer repair franchise that is known ... Samsung Galaxy devices with premium parts and accessories. Cellairis has recently set-up for business ... customers. While customers do their shopping, Cellairis can accomplish a number of mobile device ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, ... safely ride all types of amusement park rides. , The patent-pending SAFETY STRAP FOR ... easy to use and could be set up in a matter of minutes, or ...
(Date:12/9/2016)... Harrisburg, PA (PRWEB) , ... December 09, 2016 ... ... concussion education program through the Pennsylvania Cable Network (PCN) during the summer of ... Brain Injury Implementation Grant provided by the United States Department of Health and ...
(Date:12/8/2016)... ... 2016 , ... ZyDoc , a New York-based medical ... Capture Methods for Input to Electronic Health Records: A Comparative Usability Study” has ... usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s MediSapien™ natural ...
(Date:12/8/2016)... Boston (PRWEB) , ... December 08, 2016 , ... ... shareholders with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. ... sponsor of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)...  Eli Lilly and Company (NYSE: LLY ... EXPEDITION3 trial at the 9 th Clinical Trials ... did not meet the primary endpoint in the EXPEDITION3 ... with mild dementia due to Alzheimer,s disease (AD), and ... the treatment of mild dementia due to AD. ...
(Date:12/8/2016)... QUEBEC CITY , Dec. 8, 2016 /PRNewswire/ ... key US patents for improving the accuracy, reproducibility ... CD images in long and small bone orthopaedic ... proprietary approach to creating personalized orthopaedic restorations based ... create personalized orthopaedic restorations, the company harnesses the ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, ... has obtained proof-of-mechanism for neflamapimod (previously code named ... Phase 2a clinical trials that demonstrated significant Alzheimer,s ... 302 (12-week treatment) and Study 303 (6-week treatment) ... Trials in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: